The Future of Real-World Evidence: Pharma’s Next Moves

Life Sciences, Clinical Trials, Commercialization & HEOR, Pharmacovigilance,
  • Wednesday, December 07, 2022

Throughout the pharma industry, real-world evidence (RWE) is leveraged across organizations for key decision-making within a therapy’s life cycle — from R&D to new US Food and Drug Administration (FDA) drug submissions to commercial strategy operations.

Companies are choosing to invest heavily to build in-house capabilities to leverage RWE efficiently. But questions remain, especially for organizations that are just beginning to apply RWE. How can RWE be made more accessible to stakeholders across the enterprise? What are the most practical applications of RWE to accelerate research and commercialization? And, how will pharma continue to utilize RWE as an end-to-end capability to improve outcomes and meet business goals?

Two pharma giants, Pfizer and Boehringer Ingelheim, have built RWE centers of excellence (CoE), acting as the heart of real-world data (RWD) and RWE for the broader organization. These CoEs house RWE experts and support the clinical and commercial teams to achieve their goals.

In this webinar, Paul Petraro, Executive Director, Global Head RWE Analytic Center of Excellence, at Boehringer Ingelheim, Tom Dougherty, Director of RWE Partnerships and Innovation at Pfizer, along with moderator Sapna Prasad, Senior Director, Clarify Insights, Clarify Health, will discuss the future of RWE in pharma. Register now and discover:

  • The importance of RWE as an end-to-end capability
  • Meaningful ways to leverage RWE for business growth today and in the future
  • Obstacles and roadblocks to future success and implementation

Speakers

http://Paul%20Petraro,%20Boehringer%20Ingelheim

Paul Petraro, Executive Director, Global Head RWE Analytic Center of Excellence, Boehringer Ingelheim

Paul Petraro is a trained epidemiologist with a Master of Public Health from Emory University and an ScD from Harvard University. Paul has worked at Pfizer, Amgen, Bayer, Novo Nordisk and Regeneron before taking his current position as the Global Head of the Real-World Evidence Analytic Center of Excellence.

Bringing more than 15 years of experience in public and private research, Paul is an epidemiological professional who drives RWE and advances his organization to the level of excellence required to support data-driven decision-making in bringing value to patients. In addition, he has a strong background in epidemiologic methods and real-world evidence (RWE), including observational and experimental study designs and analysis, value evidence and outcomes, health economics and outcomes research.

Message Presenter
http://Tom%20Dougherty,%20Pfizer

Tom Dougherty, Director of RWE Partnerships and Innovation, Pfizer

Tom Dougherty is the Director of RWE Partnerships and Innovation at Pfizer within their RWE Center of Excellence. He is responsible for scouting, developing and launching therapeutic area-specific external data partnerships and bringing novel technologies into Pfizer.

Prior to joining Pfizer, Tom was the Director of Strategic Accounts for Premier Applied Sciences where he supported life science organizations on population health improvement solutions and real-world data partnerships.

Tom has over 15 years of experience in healthcare with Merck, GE Healthcare and Boston Scientific. He received a bachelor’s degree in chemistry and an MBA from Villanova University.

Message Presenter
http://Sapna%20Prasad,%20Clarify%20Health,%20(Moderator)

Sapna Prasad, Senior Director, Clarify Insights, Clarify Health, (Moderator)

Sapna brings over 10 years of experience working with different healthcare organizations in pharmacoeconomic and biomedical research. At Clarify, Sapna leads the Clarify Insights team, delivering data-driven advanced analytics to Clarify’s Payer, Provider and Life Sciences customers. Prior to Clarify, Sapna was the Pharmacoeconomic Specialist at Yale Cancer Center, focused on building data-driven health economics and outcomes research programs in oncology.

Sapna holds a PhD in health economics from the University of Texas School of Public Health, an MSc in health, community and development from the London School of Economics and a BA from Baylor University in journalism and biology.

Message Presenter

Who Should Attend?

Professionals from pharmaceutical, biotech, or clinical research organizations that are focused in:

  • Real World Evidence (RWE)
  • Health Outcomes and Research (HEOR)
  • Outcomes Groups
  • Commercial and Marketing
  • Analytics
  • Value-Based Medicine
  • Evidence Management
  • Clinical R&D
  • Comparative Effectiveness/Research
  • Clinical Data
  • Bioinformatics/Analytics
  • Epidemiology
  • Pharmacoeconomics
  • Pharmacovigilance

What You Will Learn

  • The importance of real-world evidence (RWE) as an end-to-end capability
  • Meaningful ways to leverage RWE for business growth today and in the future
  • Obstacles and roadblocks to future success and implementation

Xtalks Partner

Clarify Health

Clarify Health is an enterprise analytics and value-based payments platform company that delivers end-to-end intelligence on every patient journey, empowering payers, providers, and life sciences companies to make better care decisions. Its unified platform, Atlas, maps over 300 million patient journeys, generates over 18 billion AI-powered predictions and delivers insights with speed and precision via cloud software applications.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account